| Name | Title | Contact Details |
|---|
Odonate Therapeutics™ is dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, an investigational, orally administered taxane. We are conducting our multinational, multicenter, randomized, Phase 3 study in locally advanced or metastatic breast cancer (MBC), known as CONTESSA. Our goal is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
At Molecular Devices, we enable our customers to unravel the complexity of biological systems. Our innovative analytical solutions for cell and protein biology enable our customers to see more, do more, and know more, and to answer life`s most important questions. We are one of the world`s leading providers of high-performance bioanalytical measurement solutions for life science research, pharmaceutical and biotherapeutic development. With over 130,000 placements in laboratories around the world, our instruments have catalyzed brilliant scientific research described in over 25,000 peer reviewed publications. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products empower scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Our headquarters are in Silicon Valley, the hub of technology and innovation, with offices around the globe employing close to 1,000 highly skilled and passionate associates.
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Our shared purpose to serve patients in need drives us to find answers, change the world, and create a legacy. Alexion`s three highly innovative therapies treat patients with four severe and ultra-rare diseases, and we are committed to developing additional therapies that have the potential to transform patients` lives. Today, Alexion is advancing the most robust rare disease pipeline in the biotech industry, which, in addition to our complement and metabolic clinical programs, includes more than 30 diverse preclinical programs across a range of therapeutic modalities. Alexion has more than 3,000 employees serving patients in 50 countries. Our global headquarters and research operations are based in New Haven, Connecticut and our EMEA headquarters are in Zürich, Switzerland. We also have global supply chain and operations headquarters in Ireland, manufacturing facilities in the United States, and local and regional operations in countries around the world. Alexion was ranked number 5 by Science magazine in its Top Employer Survey and has also been ranked as one of the top companies on the Forbes "World`s Most Innovative Companies" list every year since 2012.
Keros Therapeutics is dedicated to the discovery and development of novel therapeutics for neuromuscular diseases
Facet Biotech Corporation is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.